Compound collections are a valuable corporate asset capable of being utilised to promote and drive innovation in early-stage drug discovery.

In our article in the EBR journal, we review current models aiming to maximise the return on investment of compound collections. We also examine some of the benefits and issues we have encountered, whilst acting as drug discovery innovation facilitators, through compound collection-sharing collaborations.

We are keen to hear your comments.